Related Experiment Videos
Management of aortic arch interruption with prostaglandin E1 infusion and microporous expanded
Insights
Prostaglandin E1 infusion improved circulation in infants with aortic arch interruption. Surgical repair with expanded polytetrafluoroethylene grafts showed good short-term patency, but long-term survival was limited by complex cardiac defects.
Area of Science:
- Pediatric Cardiology
- Congenital Heart Disease
- Surgical Innovation
Background:
- Interruption of the aortic arch is a critical congenital heart defect requiring timely intervention.
- Prostaglandin E1 is a vasodilator that can improve systemic circulation in neonates with ductal-dependent lesions.
- Expanded polytetrafluoroethylene (ePTFE) grafts are used in cardiovascular surgery.
Purpose of the Study:
- To evaluate the efficacy of Prostaglandin E1 infusion and ePTFE grafts in managing infants with interruption of the aortic arch.
- To assess the short-term and long-term outcomes of this combined therapeutic approach.
Main Methods:
- Retrospective review of eight infants (<4 days old) with interruption of the aortic arch.
- Administration of Prostaglandin E1 infusion to six infants.
- Aortic reconstruction using ePTFE grafts in seven infants.
- Follow-up for up to 3 years.
Main Results:
- Five of six infants receiving Prostaglandin E1 showed significant improvement in lower limb pulses and metabolic acidosis.
- No adverse effects were noted from Prostaglandin E1.
- Seven infants underwent successful aortic reconstruction with ePTFE grafts, with no operative deaths.
- One graft obstruction occurred during follow-up, successfully revised.
- High long-term mortality (62%) primarily due to associated cardiac malformations.
Conclusions:
- Prostaglandin E1 is a safe and effective temporary measure for hemodynamic support in neonates with aortic arch interruption.
- ePTFE grafts demonstrate favorable short-term patency for aortic reconstruction in this population.
- Associated complex cardiac malformations remain the primary determinant of long-term survival.
Abstract:
Prostaglandin E1 infusion and a microporous expanded polytetrafluoroethylene graft were used in the management of eight infants, all less than 4 days old, with interruption of the aortic arch. Five of the six infants receiving prostaglandin E1 responded dramatically to this therapy, with return of lower limb pulses and lessening of metabolic acidosis. There were no adverse effects attributable to the prostaglandin E1 infusion. Seven infants subsequently underwent aortic reconstruction with a polytetrafluoroethylene graft. There were no operative deaths, and in up to 3 years of follow-up of these patients, graft obstruction occurred in only one patient and this graft was successfully revised. The long-term mortality rate was high (62 percent); all deaths but one were attributable either to the palliation or to the total correction of the associated cardiac malformations.